Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

70.99USD
24 Sep 2018
Change (% chg)

$-0.11 (-0.15%)
Prev Close
$71.10
Open
$70.89
Day's High
$71.30
Day's Low
$70.89
Volume
146,218
Avg. Vol
2,820,553
52-wk High
$71.57
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 30.93 32.76
EPS (TTM): 1.84 -- --
ROI: 6.58 15.07 14.61
ROE: 12.28 16.59 16.33

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

10 Sep 2018

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON, Sept 10 Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

10 Sep 2018

Factbox - Challenges facing German pharmaceutical company Bayer

FRANKFURT Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters.

04 Sep 2018

Factbox: Challenges facing German pharmaceutical company Bayer

FRANKFURT Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters.

04 Sep 2018

FDA approves two new HIV drugs from Merck

Merck & Co Inc said on Thursday the U.S. Food And Drug Administration approved two of its HIV oral drugs, nearly two months ahead of schedule.

30 Aug 2018

UPDATE 1-FDA approves two new HIV drugs from Merck

Aug 30 Merck & Co Inc said on Thursday the U.S. Food And Drug Administration approved two of its HIV oral drugs, nearly two months ahead of schedule.

30 Aug 2018

FDA approves two new HIV drugs from Merck

Aug 30 Drugmaker Merck & Co Inc said on Thursday the U.S. Food And Drug Administration approved two of its oral medicines to treat HIV patients.

30 Aug 2018

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

27 Aug 2018

UPDATE 1- Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge

Aug 27 Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

27 Aug 2018

Esperion says combo therapy lowers cholesterol level by 35 pct

Aug 27 Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study. The study evaluated the efficacy and safety of the bempedoic acid-ezetimibe combination pill compared with bempedoic acid, ezetimibe or placebo in 382 high-risk patients. The 12-week study showed a 35 percent reduction in low-density lipoprotein cholesterol (LDL-C) for the combination pill compared to

27 Aug 2018

Competitors

Earnings vs. Estimates